Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Trial Profile

Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANGAEA
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2017 Results assessing safety and adherence of fingolimod treatment in daily clinical practice for up to five years (n=300, data cut-off Jan 2017), presented at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Results of the five year interim analysis of PANGAEA (n=300 ; data cut off: Jan 2017) presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Comparison of baseline data from two studies (PANGAEA and PANGAEA 2.0) presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top